KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Asset Writedowns and Impairment: 2017-2025

Historic Asset Writedowns and Impairment for Elanco Animal Health (ELAN) over the last 4 years, with Sep 2025 value amounting to $24.0 million.

  • Elanco Animal Health's Asset Writedowns and Impairment rose 60.00% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year decrease of 33.02%. This contributed to the annual value of $81.0 million for FY2024, which is 153.12% up from last year.
  • Per Elanco Animal Health's latest filing, its Asset Writedowns and Impairment stood at $24.0 million for Q3 2025, which was up 380.00% from $5.0 million recorded in Q4 2024.
  • Elanco Animal Health's 5-year Asset Writedowns and Impairment high stood at $269.0 million for Q2 2021, and its period low was $5.0 million during Q3 2023.
  • In the last 3 years, Elanco Animal Health's Asset Writedowns and Impairment had a median value of $15.0 million in 2024 and averaged $15.2 million.
  • As far as peak fluctuations go, Elanco Animal Health's Asset Writedowns and Impairment spiked by 8,866.67% in 2021, and later plummeted by 81.48% in 2024.
  • Elanco Animal Health's Asset Writedowns and Impairment (Quarterly) stood at $11.0 million in 2021, then slumped by 78.07% to $59.0 million in 2022, then reached $27.0 million in 2023, then tumbled by 81.48% to $5.0 million in 2024, then surged by 60.00% to $24.0 million in 2025.
  • Its last three reported values are $24.0 million in Q3 2025, $5.0 million for Q4 2024, and $15.0 million during Q3 2024.